EXELIXIS INC (1EXEL.MI) Stock Overview
Europe - BIT:1EXEL - US30161Q1040 - Common Stock
1EXEL.MI Key Statistics, Chart & Performance
The current stock price of 1EXEL.MI is 30.7 EUR.
1EXEL.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.47 | 345.19B | ||
| AMG.DE | AMGEN INC | 13.3 | 134.20B | ||
| 1GILD.MI | GILEAD SCIENCES INC | 15.92 | 131.38B | ||
| GIS.DE | GILEAD SCIENCES INC | 15.42 | 127.23B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 24.9 | 92.90B | ||
| ARGX.BR | ARGENX SE | 95.85 | 43.79B | ||
| 1AE.DE | ARGENX SE | 95.77 | 43.75B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.95B | ||
| IDP.DE | BIOGEN INC | 9.33 | 18.80B | ||
| 0QF.DE | MODERNA INC | N/A | 8.79B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.99B | ||
| ABVX.PA | ABIVAX SA | N/A | 6.32B |
Related stock screener links
About 1EXEL.MI
Company Profile
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,147 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Company Info
EXELIXIS INC
1851 Harbor Bay Parkway
Alameda CALIFORNIA US
Employees: 1147
Phone: 16508377000
EXELIXIS INC / 1EXEL.MI FAQ
Can you describe the business of EXELIXIS INC?
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,147 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
What is the current price of 1EXEL stock?
The current stock price of 1EXEL.MI is 30.7 EUR. The price decreased by -8.49% in the last trading session.
Does EXELIXIS INC pay dividends?
1EXEL.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1EXEL stock?
1EXEL.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
Can you provide the PE ratio for 1EXEL stock?
The PE ratio for EXELIXIS INC (1EXEL.MI) is 17.15. This is based on the reported non-GAAP earnings per share of 1.79 and the current share price of 30.7 EUR.
Is EXELIXIS INC (1EXEL.MI) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1EXEL.MI.
What is the employee count for 1EXEL stock?
EXELIXIS INC (1EXEL.MI) currently has 1147 employees.
1EXEL.MI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 1EXEL.MI.
1EXEL.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to 1EXEL.MI. 1EXEL.MI gets an excellent profitability rating and is at the same time showing great financial health properties.
1EXEL.MI Financial Highlights
Over the last trailing twelve months 1EXEL.MI reported a non-GAAP Earnings per Share(EPS) of 1.79. The EPS increased by 67.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.01% | ||
| ROA | 22.49% | ||
| ROE | 29.62% | ||
| Debt/Equity | 0 |
1EXEL.MI Forecast & Estimates
For the next year, analysts expect an EPS growth of 30.7% and a revenue growth 7.16% for 1EXEL.MI